课题基金 / 基金详情

A20 (TNFAIP3) Regulation of Intestinal Immune Homeostasis

A20 (TNFAIP3) Regulation of Intestinal Immune Homeostasis
A20 (TNFAIP3) 肠道免疫稳态的调节
批准号:
8328947
负责人:
Timothy Then-Chioh Lu
金额:
$13.04万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-07 至 2012-10-12

项目摘要

项目成果

Timothy Then-Chioh Lu的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):核因子(NF)-kB信号对维持肠道免疫稳态很重要。不适当的核因子-kB活性会导致炎症性肠病(IBD),因此必须严格控制。泛素修饰蛋白A20(也称为TNFa诱导蛋白3,TNFAIP3)是核因子-kB信号的关键调节因子,A20缺陷小鼠因自发全身炎症和恶病质而发展为自发性肠道炎症并在围产期死亡。最近的遗传学研究发现,TNFAIP3是与炎症性肠病相关的候选基因。因此,了解A20如何调节肠道免疫动态平衡对于了解IBD的发病机制和开发治疗IBD患者的新疗法至关重要。A20是一种独特的泛素修饰酶,具有脱泛素和泛素连接酶活性。初步数据表明,A20在抑制肿瘤坏死因子、TLR和NOD信号转导以及预防自发性肠炎和IBD方面起着关键作用。拟议的研究有三个具体目标:1)表征和定义A20泛素修饰结构域如何限制肿瘤坏死因子(TNF)信号转导;2)表征和定义A20泛素修饰结构域如何限制Toll样受体(TLR)信号转导;以及3)确定A20泛素修饰结构域如何参与限制炎症性肠病的发展。这些研究将提供对A20如何限制炎症信号级联和调节肠道免疫动态平衡的机械性见解。这些研究将为IBD新疗法的开发提供潜在的新线索。拟进行的研究将由Averil Ma博士指导进行。与拟议的研究出版物和职业时间表一起,已经制定了一项职业发展计划,其中包括授课课程、研究研讨会和演讲以及期刊俱乐部。一个由在IBD、免疫学、人类遗传学和细胞凋亡生物学领域拥有专业知识的国际知名导师、合作者和顾问组成的职业发展委员会将有助于确保Lu博士达到拟议的里程碑。拟议的研究将为R01拨款奠定坚实的基础,并使卢博士成为粘膜免疫学和IBD的独立研究员。
英文摘要
DESCRIPTION (provided by applicant): Nuclear Factor (NF)-kB signaling is important for the maintenance of intestinal immune homeostasis. Inappropriate NF-kB activity results in inflammatory bowel disease (IBD) and thus must be tightly regulated. The ubiquitin-modifying protein A20 (also known as TNFa induced protein 3, TNFAIP3) is a critical regulator of NF-kB signaling as demonstrated by A20-deficient mice which develop spontaneous intestinal inflammation and die perinatally due to spontaneous systemic inflammation and cachexia. Recent genetic studies have identified TNFAIP3 as a candidate gene associated with inflammatory bowel disease. Therefore, an understanding of how A20 regulates intestinal immune homeostasis will be critical in understanding the pathogenesis of IBD and the development of novel therapeutics for patients with IBD. A20 is a unique ubiquitin-modifying enzyme with both deubiquitinating and ubiquitin ligase activity. Preliminary data suggests that A20 is critical in restricting TNF, TLR and NOD signaling and preventing in spontaneous intestinal inflammation and IBD. The proposed research has three specific aims: 1) characterize and define how the A20 ubiquitin modifying domains restrict tumor necrosis factor (TNF) signaling, 2) characterize and define how the A20 ubiquitin modifying domains restrict toll-like receptor (TLR) signaling, and 3) determine how the A20 ubiquitin modifying domains are involved in restricting the development of inflammatory bowel disease in mouse models. These studies will provide mechanistic insight into how A20 restricts inflammatory signaling cascades and regulates intestinal immune homeostasis. These studies will provide potential new leads for the development of novel therapeutics for IBD. The proposed studies will be undertaken with the mentorship of Dr. Averil Ma. A Career Development Plan including didactic courses, research seminars and presentations, and journal clubs has been developed along with a proposed research publication and career timeline. A career development committee of internationally recognized mentors, collaborators, and advisors with expertise in the fields of IBD, immunology, human genetics and apoptosis biology will help ensure that Dr. Lu meets the proposed milestones. The proposed studies will establish a firm foundation for an R01 grant and allow Dr. Lu to become an independent investigator in mucosal immunology and IBD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A20 (TNFAIP3) Regulation of Intestinal Immune Homeostasis
海外基金